Univest
Univest
  • Markets

Neuland Laboratories Share Price Outlook: Where Could It Be by 2030?

  • July 22, 2026
  • Posted by: Kashish Aggarwal
  • Category: News
No Comments
Neuland Laboratories Share Price Outlook

Neuland Laboratories share price Rs 18,913. 52W high Rs 20,089, low Rs 11,500. Market cap Rs 24,352 Cr. 2030 scenario range Rs 23,550 to Rs 39,850.

The Neuland Laboratories share price forecast for the next 3 years is a question on many investors’ minds as the stock trades at Rs 18,913, within a 52 week range of Rs 11,500 to Rs 20,089. This article lays out a scenario based Neuland Laboratories share price outlook for 2027, 2028 and 2030, built on the company’s fundamentals, sector trends and the key risks that could change the trajectory. Rather than a single number, the focus here is on the range of outcomes and the assumptions behind each one.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Neuland Laboratories Company Overview
  • Where Does Neuland Laboratories Share Price Stand Today?
  • Neuland Laboratories Share Price Forecast: Key Growth Drivers for the Next 3 Years
    • Earnings Trajectory and Return Ratios
    • Structural Tailwinds in Indian Pharmaceuticals
    • Company Specific Catalysts
    • Macro Environment and Liquidity
  • Neuland Laboratories Share Price Forecast 2027, 2028 and 2030: Scenario Analysis
  • Bull Case vs Bear Case for Neuland Laboratories Share Price
    • The Bull Case
    • The Bear Case
  • Key Risks That Could Change the Neuland Laboratories Share Price Outlook
  • Is Neuland Laboratories Worth Watching for the Long Term?
  • Conclusion
    • What is the Neuland Laboratories share price forecast for the next 3 years?
    • What is the Neuland Laboratories share price forecast for 2027?
    • What is the Neuland Laboratories share price forecast for 2028?
    • What is the current share price of Neuland Laboratories?
    • Is Neuland Laboratories a good stock for the long term?
    • What is the Neuland Laboratories share price outlook for 2030?
    • What are the key risks to the Neuland Laboratories share price forecast?

Neuland Laboratories Company Overview

Neuland Laboratories is a leading contract development and manufacturing company for active pharmaceutical ingredients, serving global generic and innovator pharmaceutical clients. Understanding the business model is the first step in framing any credible Neuland Laboratories share price forecast, because the durability of earnings ultimately decides where the stock trades.

Company Neuland Laboratories
NSE Ticker NEULANDLAB
CMP Rs 18,913
52 Week High Rs 20,089
52 Week Low Rs 11,500
Market Cap Rs 24,352 Cr
Stock PE 67.4
Book Value Rs 1,461
ROE 21.2%
ROCE 26.5%
Dividend Yield 0.18%

Where Does Neuland Laboratories Share Price Stand Today?

The stock currently trades about 6 percent below its 52 week high of Rs 20,089, which means the market has already tempered some of its optimism. For anyone building a Neuland Laboratories share price forecast, this correction matters for the Neuland Laboratories share price forecast starting point, because entry valuations have a large bearing on 3 year returns.

At the current price, Neuland Laboratories commands a market capitalisation of Rs 24,352 Cr and trades at a price to earnings multiple of 67.4. The company generates a return on equity of 21.2% and a return on capital employed of 26.5%, which places it in the category of businesses with strong return ratios. These numbers anchor the Neuland Laboratories share price forecast scenarios that follow. How the broader Nifty 50 index trades over this period will also influence the multiple investors are willing to assign to the stock.

Neuland Laboratories Share Price Forecast: Key Growth Drivers for the Next 3 Years

Four forces are likely to shape the Neuland Laboratories share price forecast between now and 2030, and together they explain most of the dispersion in this Neuland Laboratories share price forecast. Each is discussed below with its likely direction of impact.

Earnings Trajectory and Return Ratios

Stock prices ultimately follow earnings. With strong return ratios at present, the pace at which profits compound over FY27 to FY30 will be the single biggest determinant of the Neuland Laboratories share price forecast actually playing out. Consistent earnings delivery tends to expand valuation multiples, while misses compress them quickly.

Structural Tailwinds in Indian Pharmaceuticals

The Indian pharmaceutical market continues to grow in high single to low double digits, supported by chronic disease prevalence, better diagnosis rates and premiumisation of therapies. Companies with strong brand equity and field force productivity, like Neuland Laboratories, are positioned to grow ahead of the market. Sector trends are visible in the Nifty Pharma index, which serves as a useful barometer for the space.

Within the space, investors often benchmark Neuland Laboratories against peers such as Divis Laboratories, Laurus Labs and Aarti Pharmalabs on growth and valuations before forming a view on the Neuland Laboratories share price forecast.

Company Specific Catalysts

The bull case for Neuland Laboratories rests on rising global demand for outsourced API manufacturing and its growing CDMO relationships with innovator pharma companies. If these play out on schedule, the Neuland Laboratories share price forecast for 2030 could gravitate toward the upper end of the scenario range discussed below.

Macro Environment and Liquidity

The RBI rate cycle, FII flows into Indian equities and overall market valuations will influence the multiple investors are willing to pay. A benign macro backdrop supports the optimistic end of any Neuland Laboratories share price forecast, while global risk aversion would do the opposite to the Neuland Laboratories share price outlook.

Neuland Laboratories Share Price Forecast 2027, 2028 and 2030: Scenario Analysis

The table below presents a scenario based Neuland Laboratories share price forecast using compounded annual growth assumptions applied to the current market price of Rs 18,913. These are illustrative ranges, not point predictions, and actual outcomes can fall outside them.

Year Bear Case Base Case Bull Case Assumption
2027 Rs 20,350 Rs 22,400 Rs 24,250 5% to 18% CAGR on CMP
2028 Rs 21,350 Rs 25,100 Rs 28,600 5% to 18% CAGR on CMP
2030 Rs 23,550 Rs 31,500 Rs 39,850 5% to 18% CAGR on CMP

In the base case scenario of this Neuland Laboratories share price forecast, the 2030 level works out to roughly Rs 31,500, implying steady compounding from today’s levels. The bull case of Rs 39,850 assumes rising global demand for outsourced API manufacturing and its growing CDMO relationships with innovator pharma companies delivers ahead of expectations, while the bear case of Rs 23,550 captures a scenario where growth stalls. That is an outcome band of about 25 percent to 111 percent over the period.

Consult a SEBI Registered Investment Advisor Before Acting on Any Forecast

Bull Case vs Bear Case for Neuland Laboratories Share Price

The Bull Case

The optimistic Neuland Laboratories share price forecast assumes rising global demand for outsourced API manufacturing and its growing CDMO relationships with innovator pharma companies. Combined with supportive sector conditions, this could lift both earnings and the valuation multiple, pushing the stock toward Rs 39,850 by 2030.

The Bear Case

The cautious view centres on the fact that client concentration among a few large pharma partners and regulatory compliance across export markets are key risks. If these pressures dominate, the Neuland Laboratories share price forecast would skew toward the lower band and the stock could stagnate near Rs 23,550 even by 2030, underperforming broader indices.

Key Risks That Could Change the Neuland Laboratories Share Price Outlook

  • Execution risk: Delays in strategy execution or capacity plans would push the earnings trajectory below the base case assumed in this Neuland Laboratories share price forecast.
  • Valuation risk: At a PE of 67.4, any earnings disappointment can trigger sharp multiple compression before fundamentals stabilise.
  • Sector risk: Client concentration among a few large pharma partners and regulatory compliance across export markets are key risks.
  • Macro risk: A global slowdown, adverse FII flows or unexpected rate moves would compress equity valuations across the market.
  • Regulatory risk: Policy, tax or compliance changes affecting the sector can alter the earnings outlook with little warning.

Is Neuland Laboratories Worth Watching for the Long Term?

For long term investors, the relevant question is not just where the Neuland Laboratories share price forecast lands in 2030 or what any single Neuland Laboratories share price forecast says today, but whether the business can compound capital through cycles. The company’s positioning around rising global demand for outsourced API manufacturing and its growing CDMO relationships with innovator pharma companies gives it a credible growth story, while the risks outlined above define what must be monitored each quarter.

Investors should track quarterly earnings, management commentary and sector data rather than anchoring to any single number from a Neuland Laboratories share price outlook. Historically, staying focused on business fundamentals has served investors better than chasing price targets, and consulting a SEBI registered advisor before investing remains the prudent approach.

Download the Univest iOS App or Univest Android App to track Neuland Laboratories share price live.

Conclusion

The Neuland Laboratories share price forecast for the next 3 years spans Rs 23,550 to Rs 39,850 by 2030 under the scenarios discussed, with a base case near Rs 31,500. Any credible Neuland Laboratories share price forecast must be updated as facts change, and the path will be decided by earnings delivery, rising global demand for outsourced API manufacturing and its growing CDMO relationships with innovator pharma companies and the broader market environment. Treat these ranges as a framework for thinking, not a promise of outcomes, and revisit the assumptions as new results come in. Consult a SEBI registered investment advisor before making any investment decision.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What is the Neuland Laboratories share price forecast for the next 3 years?

Ans. The Neuland Laboratories share price forecast for the next 3 years is scenario based rather than a single number. By 2030, the illustrative range spans Rs 23,550 in the bear case to Rs 39,850 in the bull case, with a base case near Rs 31,500, depending on earnings delivery and market conditions.

What is the Neuland Laboratories share price forecast for 2027?

Ans. For 2027, the scenario range works out to Rs 20,350 to Rs 24,250, with a base case around Rs 22,400. This assumes compounding on the current price of Rs 18,913 and is illustrative, not a guaranteed outcome.

What is the Neuland Laboratories share price forecast for 2028?

Ans. The 2028 scenario range is Rs 21,350 to Rs 28,600, with the base case near Rs 25,100. Actual levels will depend on earnings growth, sector trends and overall market valuations at the time.

What is the current share price of Neuland Laboratories?

Ans. Neuland Laboratories currently trades at around Rs 18,913 on the NSE, within a 52 week range of Rs 11,500 to Rs 20,089. Prices change continuously during market hours, so check live quotes before acting.

Is Neuland Laboratories a good stock for the long term?

Ans. Neuland Laboratories has a credible long term story built on rising global demand for outsourced API manufacturing and its growing CDMO relationships with innovator pharma companies, but it also carries risks since client concentration among a few large pharma partners and regulatory compliance across export markets are key risks. Long term suitability depends on your risk profile and portfolio, so consult a SEBI registered investment advisor before investing.

What is the Neuland Laboratories share price outlook for 2030?

Ans. The Neuland Laboratories share price outlook for 2030 spans Rs 23,550 to Rs 39,850 across bear and bull scenarios. Where the stock actually lands will be driven by profit growth, valuation multiples and macro conditions closer to that date.

What are the key risks to the Neuland Laboratories share price forecast?

Ans. The main risks are execution delays, valuation compression from the current PE of 67.4, sector specific pressures, macro shocks and regulatory changes. Any of these can push the stock below the base case scenario discussed in this article.



Author: Kashish Aggarwal
Kashish Aggarwal is a Financial Content Writer at Univest, covering Indian equity markets with a focus on share price target frameworks, technical analysis education, and sector deep-dives. Her published work spans bull-case/bear-case share price analysis, event-driven stock reactions, and beginner-friendly educational guides. Her articles blend fundamental analysis (analyst consensus targets, P/E, loan book quality, margin dynamics) with technical analysis (moving averages, 200-DMA, support/resistance levels) — giving retail investors a complete framework before any position. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards. Coverage Areas • Share price targets — REC Ltd, Adani Green Energy (bull/bear case frameworks) • Event-driven analysis — Redington (US tariff impact), Star Cement (technical breakdown) • Technical analysis education — Direct Market Access, 200-DMA, indicator interpretation • Thematic listicles — Highest Dividend Paying Stocks, Real Estate Penny Stocks, Intraday Picks • Sector coverage — IT distribution, renewable energy, infrastructure finance, cement, real estate

Leave a Reply Cancel reply